The Tisch Cancer Institute and Myeloproliferative Disease Research Consortium (MPD-RC), Mount Sinai School of Medicine, New York, NY 10029, USA.
Blood Rev. 2012 Mar;26(2):81-95. doi: 10.1016/j.blre.2011.11.002. Epub 2011 Dec 15.
Blood transfusion is indispensable for modern medicine. In developed countries, the blood supply is adequate and safe but blood for alloimmunized patients is often unavailable. Concerns are increasing that donations may become inadequate in the future as the population ages prompting a search for alternative transfusion products. Improvements in culture conditions and proof-of-principle studies in animal models have suggested that ex-vivo expanded red cells may represent such a product. Compared to other cell therapies transfusion poses the unique challenge of requiring great cell doses (2.5×10(12) cells vs 10(7) cells). Although production of such cell numbers is theoretically possible, current technologies generate red cells in numbers sufficient only for safety studies. It is conceived that by the time these studies will be completed, technical barriers to mass cell production will have been eliminated making transfusion with ex-vivo generated red cells a reality.
输血对于现代医学来说是不可或缺的。在发达国家,血液供应充足且安全,但对于自身免疫患者的血液往往无法获得。人们越来越担心,随着人口老龄化,未来的献血可能会不足,因此需要寻找替代的输血产品。培养条件的改善和动物模型的原理验证研究表明,体外扩增的红细胞可能就是这样一种产品。与其他细胞疗法相比,输血带来了独特的挑战,需要大量的细胞剂量(2.5×10(12)个细胞比 10(7)个细胞)。虽然从理论上讲可以生产出这么多数量的细胞,但目前的技术只能产生足够数量的细胞用于安全性研究。人们设想,当这些研究完成时,大规模细胞生产的技术障碍将被消除,使体外生成的红细胞输血成为现实。